Instil Bio Inc. (TIL) - Total Assets
Based on the latest financial reports, Instil Bio Inc. (TIL) holds total assets worth $203.52 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TIL total equity for net asset value and shareholders' equity analysis.
Instil Bio Inc. - Total Assets Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s total assets have evolved over time, based on quarterly financial data.
Instil Bio Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Instil Bio Inc.'s total assets of $203.52 Million consist of 94.1% current assets and 5.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.3% |
| Accounts Receivable | $848.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Instil Bio Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Instil Bio Inc.'s current assets represent 94.1% of total assets in 2025, a decrease from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2025, down from 93.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Instil Bio Inc. Competitors by Total Assets
Key competitors of Instil Bio Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Instil Bio Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 39.53 | 15.76 | 35.43 |
| Quick Ratio | 39.53 | 15.76 | 35.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $186.59 Million | $116.57 Million | $596.43 Million |
Instil Bio Inc. - Advanced Valuation Insights
This section examines the relationship between Instil Bio Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | $203.52 Million |
| Market Capitalization | $53.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Instil Bio Inc.'s assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Instil Bio Inc.'s assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Instil Bio Inc. (2019–2025)
The table below shows the annual total assets of Instil Bio Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $203.52 Million | -22.78% |
| 2024-12-31 | $263.57 Million | -19.06% |
| 2023-12-31 | $325.63 Million | -32.46% |
| 2022-12-31 | $482.13 Million | -20.96% |
| 2021-12-31 | $609.98 Million | +91.21% |
| 2020-12-31 | $319.01 Million | +3266.53% |
| 2019-12-31 | $9.48 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more